We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Single Hardware Solution Utilizes Multiple Diagnostics Technologies

By LabMedica International staff writers
Posted on 09 Sep 2010
A single hardware solution utilizes multiple diagnostics technologies such as enzyme immunoassay (EIA), chemiluminescence, and multiplexing.

Called the ThunderBolt platform, the inaugural product is an EIA processor, with a completely open software design capable of programming virtually any EIA test.

These tests are widely used to detect and quantify substances such as peptides, proteins, antibodies, and hormones, and to diagnose diseases and conditions including infections, cancer, metabolic disorders, allergies, and autoimmune diseases.

In a single, easily configured run, the flexible ThunderBolt EIA processor can process multiple microtiter plates, while also running up to eight different simultaneous assays. More...
With an onboard reader, the fully automated processor offers a true walkaway solution for labs of any size.

The compact design takes up less than half the workspace of similar EIA automated processors on the market. Cost-effective operation makes the platform suitable for larger clinical laboratories, while it also provides the customizable capabilities needed in hospital or research laboratories.

Gold Standard Diagnostics, Corp. (Davis, CA, USA), a provider of laboratory diagnostics solutions, introduced the ThunderBolt platform at the 2010 Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), which was held at the Anaheim Convention Center (CA, USA) on July 25-29, 2010.

"The ThunderBolt platform represents a true innovation in automated diagnostics instrumentation and is the culmination of nearly 20 years of feedback from laboratory customers around the world,” says John Griffiths, president and CEO of Gold Standard Diagnostics. "By understanding what customers really need, we have been able to build a product that's the right blend of power, flexibility, and ease of use, all at a competitive price.”

GSD provides products, services, and consulting to the diagnostic and medical communities. The company has been creating and cost-effective diagnostics solutions for clinical and hospital laboratories since 2006.

Related Links:
Gold Standard Diagnostics, Corp.
American Association for Clinical Chemistry



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.